Preoperative (neoadjuvant) systemic treatment of breast cancer

Breast

Volumn 14, Issue 6, 2005, Pages 576-581

  Kaufmann, Manfred ^a   von Minckwitz, Gunter ^a   Rody, Achim ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Breast cancer; Breast conservation; Neoadjuvant treatment

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISTRESS SYNDROME; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; PARTIAL MASTECTOMY; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SENTINEL LYMPH NODE BIOPSY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 23644456477     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.08.010     Document Type: Article

References (25)

1. B. Fisher J. Bryant N. Wolmark E. Mamounas A. Brown E.R. et al. Fisher Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672-2685
2. L. Gianni J. Baselga W. Eiermann V. Guillem Porta V. Semiglazov J. Garcia-Conde et al. First report of the European cooperative trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease Proc ASCO 2002 [abstract 132]
3. J.A. Van der Hage C.J.H. van de Velde J.P. Julien et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European organization for research and treatment of cancer trial 10902 J Clin Oncol 19 2001 4224-4237
4. S.M. Scholl A. Fouquet B. Asselain et al. Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomised trial Eur J Cancer 30A 1994 645-652
5. G. Von Minckwitz S.D. Costa G. Raab J.U. Blohmer H. Eidtmann J. Hilfrich et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 2001 3506-3515
6. G. Von Minckwitz G. Raab A. Caputo M. Schuette J. Hilfrich J.U. Blohmer et al. Dexorubicin with cyclophosphamide followed by Docetaxel weekly every 21 days compared with Doxorubicin and Docetaxel every 14 days as preoperative treatment in operable breast cancer. The Geparduo study of the German Breast Group J Clin Oncol 23 2005 2676-2785
7. M. Untch G. Konecny N. Ditsch Y. Sorokina V. Volker Moebus B. Muck et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study Proc ASCO 2002 [abstract 133]
8. G. Von Minckwitz J.U. Blohmer G. Raab A. Lohr B. Gerber G. Heinrich et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study Ann Oncol 16 2005 56-63
9. I. Smith M. Dowsett Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial SABCS 2003 [abstract 1]
10. W. Eiermann S. Paepke J. Appfelstaedt A. Llombart-Cussac J. Eremin J. Vinholes et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol 12 2001 1527-1532
11. V.F. Semiglazov V. Semiglazov V. Ivanov A. Bozhok E. Ziltsova R. Paltuev et al. The relative efficacy of neoadjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER-positive breast cancer Proc ASCO 2004 [abstract 519]
12. H.D. Bear S. Anderson A. Brown R. Smith E.P. Mamounas B. Fisher et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national Surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 21 2003 4165-4174
13. H.D. Bear S. Anderson R.E. Smith A. Robidoux M.S. Kahlenberg R.G. Margolese et al. A randomized trial comparing preoperative doxorubicin/ cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: Results of NSABP SABCS 2004 [abstract 26]
14. M. Cristofanilli A. Gonzalez-Angulo N. Sneige S.W. Kau K. Broglio R.L. Theriault et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes J Clin Oncol 23 2005 41-48
15. A.U. Buzdar K. Hunt T. Smith D. Francis M. Ewer D. Booser et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease Proc ASCO 2004 [abstract 520]
16. M. Kaufmann G. von Minckwitz R. Smith V. Valero L. Gianni W. Eiermann et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations J Clin Oncol 21 2003 2600-2608
17. N. Wolmark J. Wang E. Mamounas J. Bryant B. Fisher Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18 J Natl Cancer Inst Monogr 30 2001 96-102
18. A. Makris T.J. Powles S.E. Ashley J. Chang T. Hickish V.A. Tidy et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1998 1179-1184
19. B.A. Pockaj R.J. Gray Surgical management of locally advanced breast cancer Proc ASCO 2004 85-91 (educational)
20. M.C. Green A.U. Buzdar T. Smith Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC - final results of a prospective phase III randomised trial Proc ASCO 2002 [abstract 125]
21. A. Ahr T. Karn C. Solbach T. Seiter K. Strebhardt U. Holtrich et al. Identification of high risk breast-cancer patients by gene expression profiling Lancet 359 2002 131-132
22. L.J. Van't Veer H. Dai M.J. van de Vijver Y.D. He A.A. Hart M. Mao et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530-536
23. J.C. Chang E.C. Wooten A. Tsimelzon S.G. Hilsenbeck M.C. Gutierrez R. Elledge et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362-369
24. H.M. Kuerer L.A. Newman T.L. Smith F.C. Ames K.K. Hunt K. Dhingra et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460-469
25. M. Colleoni S. Gelber A.S. Coates M. Castiglione-Gertsch R.D. Gelber K. et al. Price Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer J Clin Oncol 19 2001 4141-4149